Telios Pharma, Inc.
12
4
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Role: lead
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Role: lead
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
Role: lead
A Study Of TL-925 For The Treatment of AC
Role: lead
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Role: lead
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
Role: lead
A Study of TL-925 as a Treatment for Dry Eye Disease
Role: lead
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Role: lead
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Role: lead
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Role: lead
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Role: collaborator
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Role: lead
All 12 trials loaded